Insider · CIK 0001536290
Matthew C Kapusta
Files at QURE (uniQure N.V.). First filing Dec 10, 2024, latest Mar 6, 2026.
Matthew C Kapusta files SEC Form 4 as CEO and director at QURE (uniQure N.V.). Since Dec 10, 2024, Matthew C Kapusta has reported 0 open-market buys worth $0 and 8 open-market sells worth $12M, the latest filed on Mar 6, 2026.
A track record needs three past buys with six months of prices behind them; Matthew C Kapusta has 0, so none is measured yet.
The newest scored trade: sold $132k of QURE on Mar 4, 2026, filed Mar 6, 2026, scored 51 (moderate). In the last 12 months: 0 buys worth $0 and 3 sells worth $770k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
QURE: uniQure N.V.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | uniQure N.V. | $132k 14,581 shares | -2% | +8% from low-87% from high | |
| 55Moderate | uniQure N.V. | $343k 34,437 shares | -5% | +26% from low-85% from high | |
| 54Moderate | uniQure N.V. | $295k 12,378 shares | -2% | +198% from low-65% from high | |
| 33Weak | uniQure N.V. | $9.4M 226,316 shares | -26% | +946% from low0% from high | |
| 54Moderate | uniQure N.V. | $292k 28,341 shares | -4% | - | |
| 55Moderate | uniQure N.V. | $362k 33,444 shares | -6% | - | |
| 28Weak | uniQure N.V. | $1.5M 100,000 shares | -14% | - | |
| 38Weak | uniQure N.V. | $26k 3,418 shares | -1% | - |
Transactions
Every row this insider has filed, 25 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | QURE uniQure N.V. | AGrant or award Ordinary Shares | +70,600 | $0.00 | $0 | 675,239 | Mar 6, 2026 |
| Mar 4, 2026 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -14,581 | $9.06 | $132k | 660,658 | Mar 6, 2026 |
| Mar 4, 2026 | QURE uniQure N.V. | AGrant or award Stock Option (Right to Buy)derivative | +113,800 | $0.00 | $0 | 113,800 | Mar 6, 2026 |
| Mar 2, 2026 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -34,437 | $9.95 | $343k | 604,639 | Mar 4, 2026 |
| Feb 25, 2026 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -12,378 | $23.86 | $295k | 639,076 | Feb 27, 2026 |
| Sep 24, 2025 | QURE uniQure N.V. | MOption exercise Ordinary Shares10b5-1 | +51,316 | $7.53 | $386k | 702,770 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | MOption exercise Ordinary Shares10b5-1 | +175,000 | $6.22 | $1.1M | 877,770 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -51,316 | $39.59 | $2.0M | 826,454 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $40.04 | $2.4M | 766,454 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -49,978 | $40.68 | $2.0M | 716,476 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -5,022 | $41.69 | $209k | 711,454 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -60,000 | $45.10 | $2.7M | 651,454 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -51,316 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Sep 24, 2025 | QURE uniQure N.V. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -175,000 | $0.00 | $0 | 0 | Sep 26, 2025 |
| Mar 3, 2025 | QURE uniQure N.V. | AGrant or award Ordinary Shares | +99,000 | $0.00 | $0 | 679,795 | Mar 5, 2025 |
| Mar 4, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -28,341 | $10.29 | $292k | 651,454 | Mar 5, 2025 |
| Mar 3, 2025 | QURE uniQure N.V. | AGrant or award Stock Option (Right to Buy)derivative | +171,000 | $0.00 | $0 | 171,000 | Mar 5, 2025 |
| Feb 25, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -26,727 | $10.70 | $286k | 571,188 | Feb 27, 2025 |
| Feb 26, 2025 | QURE uniQure N.V. | AGrant or award Ordinary Shares | +16,324 | $0.00 | $0 | 587,512 | Feb 27, 2025 |
| Feb 27, 2025 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -6,717 | $11.32 | $76k | 580,795 | Feb 27, 2025 |
| Dec 10, 2024 | QURE uniQure N.V. | MOption exercise Ordinary Shares10b5-1 | +100,000 | $14.71 | $1.5M | 697,915 | Dec 12, 2024 |
| Dec 10, 2024 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares10b5-1 | -100,000 | $15.03 | $1.5M | 597,915 | Dec 12, 2024 |
| Dec 10, 2024 | QURE uniQure N.V. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -100,000 | $0.00 | $0 | 0 | Dec 12, 2024 |
| Dec 8, 2024 | QURE uniQure N.V. | AGrant or award Ordinary Shares | +10,494 | $0.00 | $0 | 601,333 | Dec 10, 2024 |
| Dec 9, 2024 | QURE uniQure N.V. | SOpen-market sale Ordinary Shares | -3,418 | $7.63 | $26k | 597,915 | Dec 10, 2024 |
Questions about Matthew C Kapusta
Answered from the filings on this page, as of the latest one.
Is Matthew C Kapusta buying or selling?
In the last 12 months Matthew C Kapusta reported 0 open-market buys worth $0 and 3 open-market sells worth $770k on SEC Form 4; the latest was sold $132k of QURE on Mar 4, 2026. Grants, option exercises and tax withholding are not counted.
How did Matthew C Kapusta's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matthew C Kapusta has 0.
Where does Matthew C Kapusta file Form 4?
Matthew C Kapusta has filed Form 4 at QURE (uniQure N.V.) as CEO, Managing Director. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.